US20080153862A1 - Spiropiperidine derivatives - Google Patents
Spiropiperidine derivatives Download PDFInfo
- Publication number
- US20080153862A1 US20080153862A1 US11/955,460 US95546007A US2008153862A1 US 20080153862 A1 US20080153862 A1 US 20080153862A1 US 95546007 A US95546007 A US 95546007A US 2008153862 A1 US2008153862 A1 US 2008153862A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- halo
- hydrogen
- alkoxy
- spiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1=C([9*])C([8*])=C([7*])C(C(=O)N2CC(*)C3(C[Y]C4=C3C([4*])=C([3*])C([2*])=C4[1*])C([5*])C2)=C1* Chemical compound *C1=C([9*])C([8*])=C([7*])C(C(=O)N2CC(*)C3(C[Y]C4=C3C([4*])=C([3*])C([2*])=C4[1*])C([5*])C2)=C1* 0.000 description 26
- XQFDNPKBFYSFIW-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)N2CCC3(C=CC4=CC=CC=C43)CC2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)N2CCC3(C=CC4=CC=CC=C43)CC2)C=C1 XQFDNPKBFYSFIW-UHFFFAOYSA-N 0.000 description 2
- CPDBKCBTUIMRDS-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)OCC2=C3C=CC=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)OCC2=C3C=CC=C2)C=C1 CPDBKCBTUIMRDS-UHFFFAOYSA-N 0.000 description 2
- IIRUWIJPAPDAOL-UHFFFAOYSA-N CC1(C)C(=O)NC2=CC(C(=O)N3CCC4(CC3)OCC3=CC=CC=C34)=CC=C21 Chemical compound CC1(C)C(=O)NC2=CC(C(=O)N3CCC4(CC3)OCC3=CC=CC=C34)=CC=C21 IIRUWIJPAPDAOL-UHFFFAOYSA-N 0.000 description 2
- ZQZPVTVYWWAKON-UHFFFAOYSA-N CCOC1=CC=C2C=CC=CC2=C1C(=O)N1CCC2(CC1)OCC1=CC=CC=C12 Chemical compound CCOC1=CC=C2C=CC=CC2=C1C(=O)N1CCC2(CC1)OCC1=CC=CC=C12 ZQZPVTVYWWAKON-UHFFFAOYSA-N 0.000 description 2
- ZXAFZCUFMNOOKX-UHFFFAOYSA-N O=C(/C1=C/C=C\C2=C1OC(F)(F)O2)N1CCC2(C=CC3=CC=CC=C32)CC1 Chemical compound O=C(/C1=C/C=C\C2=C1OC(F)(F)O2)N1CCC2(C=CC3=CC=CC=C32)CC1 ZXAFZCUFMNOOKX-UHFFFAOYSA-N 0.000 description 2
- CSGRLGLZQCDDAU-UHFFFAOYSA-N O=C(C1=CC=C(Cl)C(Cl)=C1)N1CCC2(CC1)COC1=C2C=CC=C1 Chemical compound O=C(C1=CC=C(Cl)C(Cl)=C1)N1CCC2(CC1)COC1=C2C=CC=C1 CSGRLGLZQCDDAU-UHFFFAOYSA-N 0.000 description 2
- MSFJCNCDXXDAOS-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=CC=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=CC=C2 MSFJCNCDXXDAOS-UHFFFAOYSA-N 0.000 description 2
- KDKHRGSFCBBBCF-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)C(=O)NC2=CC=C(Br)C=C23)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)C(=O)NC2=CC=C(Br)C=C23)C=C1 KDKHRGSFCBBBCF-UHFFFAOYSA-N 0.000 description 1
- XHYSBXGLCOCGQH-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)OC(=O)C2=C3C=C(Cl)C=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)OC(=O)C2=C3C=C(Cl)C=C2)C=C1 XHYSBXGLCOCGQH-UHFFFAOYSA-N 0.000 description 1
- CBYFTNQLOARJQI-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)OC(=O)C2=C3C=CC=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)N2CCC3(CC2)OC(=O)C2=C3C=CC=C2)C=C1 CBYFTNQLOARJQI-UHFFFAOYSA-N 0.000 description 1
- WOGQBAFQIACVBF-UHFFFAOYSA-N CC1=C2C(=CC=C1)NC(=O)C21CCN(C(=O)C2=CC=C(Cl)C=C2)CC1 Chemical compound CC1=C2C(=CC=C1)NC(=O)C21CCN(C(=O)C2=CC=C(Cl)C=C2)CC1 WOGQBAFQIACVBF-UHFFFAOYSA-N 0.000 description 1
- QSVGKZGKFQNPCA-UHFFFAOYSA-N CCOC1=CC=C2C=CC=CC2=C1C(=O)N1CCC2(CC1)OCC1=C2C=CC=C1F Chemical compound CCOC1=CC=C2C=CC=CC2=C1C(=O)N1CCC2(CC1)OCC1=C2C=CC=C1F QSVGKZGKFQNPCA-UHFFFAOYSA-N 0.000 description 1
- GFPYBVVJNXTVJN-UHFFFAOYSA-N CN(CCCl)CCCl.CN1CCC2(CC1)C(=O)NC1=CC=C(Br)C=C12.CN1CCC2(CC1)C(=O)NC1=CC=CC=C12.Cl.Cl.ClCCNCCCl.N#CN1CCC2(CC1)C(=O)NC1=CC=C(Br)C=C12.O=C1CC2=CC=CC=C2N1.O=C1NC2=CC=C(Br)C=C2C12CCNCC2.OCCO Chemical compound CN(CCCl)CCCl.CN1CCC2(CC1)C(=O)NC1=CC=C(Br)C=C12.CN1CCC2(CC1)C(=O)NC1=CC=CC=C12.Cl.Cl.ClCCNCCCl.N#CN1CCC2(CC1)C(=O)NC1=CC=C(Br)C=C12.O=C1CC2=CC=CC=C2N1.O=C1NC2=CC=C(Br)C=C2C12CCNCC2.OCCO GFPYBVVJNXTVJN-UHFFFAOYSA-N 0.000 description 1
- CDXLDUPCRZGJCP-UHFFFAOYSA-N CN1CCC(=O)CC1.CN1CCC2(CC1)OC(=O)C1=CC(Br)=CC=C12.N#CN1CCC2(CC1)OC(=O)C1=CC(Br)=CC=C12.O=C(O)C1=CC(Br)=CC=C1Br.O=C1OC2(CCNCC2)C2=CC=C(Br)C=C12 Chemical compound CN1CCC(=O)CC1.CN1CCC2(CC1)OC(=O)C1=CC(Br)=CC=C12.N#CN1CCC2(CC1)OC(=O)C1=CC(Br)=CC=C12.O=C(O)C1=CC(Br)=CC=C1Br.O=C1OC2(CCNCC2)C2=CC=C(Br)C=C12 CDXLDUPCRZGJCP-UHFFFAOYSA-N 0.000 description 1
- ZMSGLGJBXKZTLM-UHFFFAOYSA-N CN1CCC(=O)CC1.CN1CCC2(CC1)OC(=O)C1=CC=C(F)C=C12.N#CN1CCC2(CC1)OC(=O)C1=CC=C(F)C=C12.O=C(O)C1=CC=C(F)C=C1Br.O=C1OC2(CCNCC2)C2=CC(OCCO)=CC=C12 Chemical compound CN1CCC(=O)CC1.CN1CCC2(CC1)OC(=O)C1=CC=C(F)C=C12.N#CN1CCC2(CC1)OC(=O)C1=CC=C(F)C=C12.O=C(O)C1=CC=C(F)C=C1Br.O=C1OC2(CCNCC2)C2=CC(OCCO)=CC=C12 ZMSGLGJBXKZTLM-UHFFFAOYSA-N 0.000 description 1
- BCLGVKYBSNARRB-UHFFFAOYSA-N COC1=CC(C(=O)N2CCC3(CC2)OCC2=CC=CC=C23)=C2NC=CC2=C1 Chemical compound COC1=CC(C(=O)N2CCC3(CC2)OCC2=CC=CC=C23)=C2NC=CC2=C1 BCLGVKYBSNARRB-UHFFFAOYSA-N 0.000 description 1
- FFEYNDFFDFQWMG-UHFFFAOYSA-N COC1=CC(C(=O)O)=C2NC=CC2=C1 Chemical compound COC1=CC(C(=O)O)=C2NC=CC2=C1 FFEYNDFFDFQWMG-UHFFFAOYSA-N 0.000 description 1
- WEPQIFGZKRVOMU-UHFFFAOYSA-N COC1=CC2=C(C=C1)C1(CCN(C(=O)C3=CC4=C(C=CC=C4)C=C3)CC1)OC2=O Chemical compound COC1=CC2=C(C=C1)C1(CCN(C(=O)C3=CC4=C(C=CC=C4)C=C3)CC1)OC2=O WEPQIFGZKRVOMU-UHFFFAOYSA-N 0.000 description 1
- YYDOGGCVYYGDQY-UHFFFAOYSA-N COC1=CC2=C(C=C1)C1(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC1)OC2=O Chemical compound COC1=CC2=C(C=C1)C1(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC1)OC2=O YYDOGGCVYYGDQY-UHFFFAOYSA-N 0.000 description 1
- AJQCPTRGJCQBPS-UHFFFAOYSA-N COC1=CC2=C(C=C1)C1(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC1)OC2=O Chemical compound COC1=CC2=C(C=C1)C1(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC1)OC2=O AJQCPTRGJCQBPS-UHFFFAOYSA-N 0.000 description 1
- VOHHGIVDPXNBBX-UHFFFAOYSA-N COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=C5NN=CC5=CC(Cl)=C4)CC3)C2=C1 Chemical compound COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=C5NN=CC5=CC(Cl)=C4)CC3)C2=C1 VOHHGIVDPXNBBX-UHFFFAOYSA-N 0.000 description 1
- OIRJBQFYGJFVIY-UHFFFAOYSA-N COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=CC=C(Cl)C(Cl)=C4)CC3)C2=C1 Chemical compound COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=CC=C(Cl)C(Cl)=C4)CC3)C2=C1 OIRJBQFYGJFVIY-UHFFFAOYSA-N 0.000 description 1
- XSXFVTGIFBUDPK-UHFFFAOYSA-N COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=CC=C5C=CC=CC5=C4)CC3)C2=C1 Chemical compound COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=CC=C5C=CC=CC5=C4)CC3)C2=C1 XSXFVTGIFBUDPK-UHFFFAOYSA-N 0.000 description 1
- VBYUJCPBTZGFSZ-UHFFFAOYSA-N COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=CC=CC(Cl)=C4Cl)CC3)C2=C1 Chemical compound COC1=CC=C2C(=O)OC3(CCN(C(=O)C4=CC=CC(Cl)=C4Cl)CC3)C2=C1 VBYUJCPBTZGFSZ-UHFFFAOYSA-N 0.000 description 1
- GIACYPOBYFPKKN-UPCLLVRISA-N C[C@H]1CN(C(=O)C2=CC=C(C(C)(C)C)C=C2)CC[C@@]12OC(=O)C1=CC=CC=C12 Chemical compound C[C@H]1CN(C(=O)C2=CC=C(C(C)(C)C)C=C2)CC[C@@]12OC(=O)C1=CC=CC=C12 GIACYPOBYFPKKN-UPCLLVRISA-N 0.000 description 1
- OEYJBCQFXHCACZ-UHFFFAOYSA-N O=C(C1=C2NC=NC2=CC=C1)N1CCC2(CC1)OCC1=CC=CC=C12 Chemical compound O=C(C1=C2NC=NC2=CC=C1)N1CCC2(CC1)OCC1=CC=CC=C12 OEYJBCQFXHCACZ-UHFFFAOYSA-N 0.000 description 1
- PTHATRVENIKYAT-UHFFFAOYSA-N O=C(C1=C2NN=CC2=CC(Cl)=C1)N1CCC2(C=CC3=CC=CC=C32)CC1 Chemical compound O=C(C1=C2NN=CC2=CC(Cl)=C1)N1CCC2(C=CC3=CC=CC=C32)CC1 PTHATRVENIKYAT-UHFFFAOYSA-N 0.000 description 1
- GYOSEZRTQKKYKD-UHFFFAOYSA-N O=C(C1=CC2=C(C=CC=C2)C=C1)N1CCC2(CC1)C(=O)NC1=CC=C(Br)C=C12 Chemical compound O=C(C1=CC2=C(C=CC=C2)C=C1)N1CCC2(CC1)C(=O)NC1=CC=C(Br)C=C12 GYOSEZRTQKKYKD-UHFFFAOYSA-N 0.000 description 1
- QBOGLNIUCCNLPT-UHFFFAOYSA-N O=C(C1=CC=C(Cl)C(Cl)=C1)N1CCC2(C=CC3=CC=CC=C32)CC1 Chemical compound O=C(C1=CC=C(Cl)C(Cl)=C1)N1CCC2(C=CC3=CC=CC=C32)CC1 QBOGLNIUCCNLPT-UHFFFAOYSA-N 0.000 description 1
- CADOGLSRVIJLSQ-UHFFFAOYSA-N O=C(C1=CC=C(Cl)C(Cl)=C1)N1CCC2(CCC3=CC=CC=C32)CC1 Chemical compound O=C(C1=CC=C(Cl)C(Cl)=C1)N1CCC2(CCC3=CC=CC=C32)CC1 CADOGLSRVIJLSQ-UHFFFAOYSA-N 0.000 description 1
- XGQZSVDVZGAZBN-UHFFFAOYSA-N O=C(C1=CC=C2C=CC=CC2=C1)N1CCC2(C=CC3=CC=CC=C32)CC1 Chemical compound O=C(C1=CC=C2C=CC=CC2=C1)N1CCC2(C=CC3=CC=CC=C32)CC1 XGQZSVDVZGAZBN-UHFFFAOYSA-N 0.000 description 1
- ZFOBQNVYTGSNAQ-UHFFFAOYSA-N O=C(C1=CC=CC(Cl)=C1Cl)N1CCC2(C=CC3=CC=CC=C32)CC1 Chemical compound O=C(C1=CC=CC(Cl)=C1Cl)N1CCC2(C=CC3=CC=CC=C32)CC1 ZFOBQNVYTGSNAQ-UHFFFAOYSA-N 0.000 description 1
- ODHVDYOFYCOETH-UHFFFAOYSA-N O=C(C1=CC=CC(Cl)=C1Cl)N1CCC2(CCC3=CC=CC=C32)CC1 Chemical compound O=C(C1=CC=CC(Cl)=C1Cl)N1CCC2(CCC3=CC=CC=C32)CC1 ODHVDYOFYCOETH-UHFFFAOYSA-N 0.000 description 1
- JHOYDPHCJOLNML-UHFFFAOYSA-N O=C(C1=CC=CC2=C1NC=C2)N1CCC2(CC1)OCC1=CC=CC=C12 Chemical compound O=C(C1=CC=CC2=C1NC=C2)N1CCC2(CC1)OCC1=CC=CC=C12 JHOYDPHCJOLNML-UHFFFAOYSA-N 0.000 description 1
- CBFVSYBEGXVQCW-UHFFFAOYSA-N O=C(C1=CC=CC2=C1OC(F)(F)O2)N1CCC2(CC1)OCC1=C2C=CC=C1 Chemical compound O=C(C1=CC=CC2=C1OC(F)(F)O2)N1CCC2(CC1)OCC1=C2C=CC=C1 CBFVSYBEGXVQCW-UHFFFAOYSA-N 0.000 description 1
- YQULIJPJWZAEEZ-UHFFFAOYSA-N O=C(C1=CC=CC2=C1OCO2)N1CCC2(CC1)OCC1=CC=CC=C12 Chemical compound O=C(C1=CC=CC2=C1OCO2)N1CCC2(CC1)OCC1=CC=CC=C12 YQULIJPJWZAEEZ-UHFFFAOYSA-N 0.000 description 1
- OGYIJVBOXJPUNY-UHFFFAOYSA-N O=C(C1=CC=CC2=CC=CC=C21)N1CCC2(CC1)OCC1=C2C=CC=C1F Chemical compound O=C(C1=CC=CC2=CC=CC=C21)N1CCC2(CC1)OCC1=C2C=CC=C1F OGYIJVBOXJPUNY-UHFFFAOYSA-N 0.000 description 1
- WIQRRACAOGHEJB-UHFFFAOYSA-N O=C(C1=CC=CC2=CC=CC=C21)N1CCC2(CC1)OCC1=CC=CC=C12 Chemical compound O=C(C1=CC=CC2=CC=CC=C21)N1CCC2(CC1)OCC1=CC=CC=C12 WIQRRACAOGHEJB-UHFFFAOYSA-N 0.000 description 1
- AXUIWMGETJDZSP-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=C4NN=CC4=CC(Cl)=C3)CC2)C2=CC=CC=C12 Chemical compound O=C1OC2(CCN(C(=O)C3=C4NN=CC4=CC(Cl)=C3)CC2)C2=CC=CC=C12 AXUIWMGETJDZSP-UHFFFAOYSA-N 0.000 description 1
- IANWWYZNKRCCGB-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=C(Br)C=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=C(Br)C=C2 IANWWYZNKRCCGB-UHFFFAOYSA-N 0.000 description 1
- KZIOQTZCNPAEKN-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=C(F)C=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=C(F)C=C2 KZIOQTZCNPAEKN-UHFFFAOYSA-N 0.000 description 1
- URKJYBMDCARDQW-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=CC(Cl)=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=CC(Cl)=C2 URKJYBMDCARDQW-UHFFFAOYSA-N 0.000 description 1
- LSWFZMRKLGQELG-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=CC(OCCO)=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=C(Cl)C(Cl)=C3)CC2)C2=C1C=CC(OCCO)=C2 LSWFZMRKLGQELG-UHFFFAOYSA-N 0.000 description 1
- TVKIVFAVBFLCFD-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=C(F)C=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=C(F)C=C2 TVKIVFAVBFLCFD-UHFFFAOYSA-N 0.000 description 1
- FBGWNTPCRQBABS-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=CC(Cl)=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=CC(Cl)=C2 FBGWNTPCRQBABS-UHFFFAOYSA-N 0.000 description 1
- FRBNPENTBDORFS-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=CC(OCCO)=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=CC(OCCO)=C2 FRBNPENTBDORFS-UHFFFAOYSA-N 0.000 description 1
- NKXZMXSHTPZOOG-UHFFFAOYSA-N O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=CC=C2 Chemical compound O=C1OC2(CCN(C(=O)C3=CC=CC(Cl)=C3Cl)CC2)C2=C1C=CC=C2 NKXZMXSHTPZOOG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Definitions
- Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus. Three vasopressin receptors, all belonging to the class I G-protein coupled receptors, are known.
- the V1a receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis, the V1b or V3 receptor is expressed in the brain and pituitary gland, the V2 receptor is expressed in the kidney where it regulates water excretion and mediates the antidiuretic effects of vasopressin.
- vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogenolysis and antidiuresis.
- vasopressin acts as a neuromodulator and is elevated in the amygdala during stress (Ebner, K., C. T. Wotjak, et al. (2002). “Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats.” Eur J Neurosci 15(2): 384-8).
- the V1a receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety.
- V1a knock-out mouse show a reduction in anxious behavior in the plus-maze, open field and light-dark box (Bielsky, I. F., S. B. Hu, et al. (2003). “Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice.” Neuropsychopharmacology ).
- the downregulation of the V1a receptor using antisense oligonucleotide injection in the septum also causes a reduction in anxious behavior (Landgraf, R., R. Gerstberger, et al. (1995). “V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.” Regul Pept 59(2): 229-39).
- the V1a receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini, L. C. and M. Morris (1999). “Endogenous vasopressin modulates the cardiovascular responses to exercise.” Ann N Y Acad Sci 897: 198-211). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the V1a receptor improves hemodynamic parameters in myocardial infarcted rats (Van Kerckhoven, R., I. Lankhuizen, et al. (2002). “Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats.” Eur J Pharmacol 449(1-2): 135-41).
- the present invention provides novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.
- R 5 and R 5 ′ are each independently hydrogen or methyl;
- R 6 is hydrogen or C 1-6 -alkyl;
- R 7 , R 7 ′, R 8 , R 8 ′ and R 9 are each independently selected from
- R 7 and R 8 , R 7 ′ and R 8 ′, R 8 and R 9 , or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
- the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the text or in the examples, or by methods known in the art.
- the compounds of formula (I) possess pharmaceutical activity, in particular they are modulators of V1a receptor activity. More particular, the compounds are antagonists of the V1a receptor. Such antagonists are useful as therapeutics in the conditions of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
- the preferred indications with regard to the present invention are the treatment of anxiety and depressive disorders.
- alkyl refers to a branched or straight-chain monovalent saturated hydrocarbon radical.
- C 1-6 -alkyl denotes a saturated straight- or branched-chain hydrocarbon group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, the isomeric pentyls and the like.
- a preferred sub-group of C 1-6 -alkyl is C 1-4 -alkyl, i.e. with 1-4 carbon atoms.
- alkylene refers to a linear or branched saturated divalent hydrocarbon radical.
- C 1-6 -alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g. methylene, ethylene, 2,2-dimethylethylene, n-propylene, 2-methylpropylene, and the like.
- alkoxy and C 1-6 -alkoxy refers to the group R′—O—, wherein R′ is alkyl or C 1-6 -alkyl as defined above.
- alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy and the like.
- a preferred sub-group of C 1-6 -alkoxy, and still more preferred alkoxy groups are methoxy and/or ethoxy.
- thioalkyl and “C 1-6 -thioalkyl” refers to the group R′—S—, wherein R′ is alkyl or C 1-6 -alkyl as defined above.
- C 1-6 -hydroxyalkyl or “C 1-6 -alkyl substituted by OH” denotes a C 1-6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxyl group.
- C 1-6 -cyanoalkyl or “C 1-6 -alkyl substituted by CN” denotes a C 1-6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a CN group.
- halo or “halogen” refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I) with fluorine, chlorine and bromine being preferred.
- halo-C 1-6 -alkyl is synonymous with “C 1-6 -haloalkyl” or “C 1-6 -alkyl substituted by halo” and means a C 1-6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
- halo-C 1-6 -alkyl examples include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
- preferred halo-C 1-6 -alkyl groups are difluoro- or trifluoro-methyl or -ethyl.
- halo-C 1-6 -alkoxy is synonymous with “C 1-6 -haloalkoxy” or “C 1-6 -alkoxy substituted by halo” and means a C 1-6 -alkoxy group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
- halogenated alkoxy groups are difluoro- or trifluoro-methoxy or -ethoxy.
- C 2-12 -alkenyl denotes a straight-chain or branched hydrocarbon residue of 2 to 12 carbon atoms comprising at least one double bond.
- a preferred sub-group of C 2-12 -alkenyl is C 2-6 -alkyenyl.
- Examples of the preferred alkenyl groups are ethenyl, propen-1-yl, propen-2-yl (allyl), buten-1-yl, buten-2-yl, buten-3-yl, penten-1-yl, penten-2-yl, penten-3-yl, penten-4-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, hexen-4-yl and hexen-5-yl, as well as those specifically illustrated by the examples herein below.
- substituents preferably means one, two or three optional substituents per ring.
- “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
- pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
- “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
- bound together to form a ring with the phenyl moiety means that the residues of the phenyl ring, which are located in ortho-position to each other, may form an anellated ring to the phenyl moiety.
- the invention further comprises individual optical isomers of the compounds herein as well as racemic and non-racemic mixtures thereof.
- R 5 and R 5 ′ are each independently hydrogen or methyl;
- R 6 is hydrogen or C 1-6 -alkyl;
- R 7 , R 7 ′, R 8 , R 8 ′, and R 9 are each independently selected from
- R 7 and R 8 , R 7 ′ and R 8 ′, R 8 and R 9 , or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
- R 1 , R 2 , R 3 and R 4 are each independently hydrogen, halo, C 1-6 -alkyl or C 1-6 -alkoxy, optionally substituted by OH.
- R 1 is hydrogen or halo, preferably hydrogen or fluoro.
- R 2 is hydrogen, halo or C 1-6 -alkoxy; preferably hydrogen, fluoro, bromo or methoxy.
- R 3 is hydrogen, halo, or C 1-6 -alkoxy, optionally substituted by OH; preferably hydrogen, chloro, bromo, methoxy or —O(CH 2 ) 2 OH.
- R 4 is hydrogen or C 1-6 -alkyl; preferably hydrogen or methyl.
- all R 1 to R 4 are hydrogen.
- one residue of R 1 to R 4 is halo and the others are hydrogen.
- one residue of R 1 to R 4 is C 1-6 -alkyl, preferably methyl, and the others are hydrogen.
- one residue of R 1 to R 4 is C 1-6 -alkoxy, optionally substituted by OH, preferably methoxy or —O(CH 2 ) 2 OH, and the others are hydrogen.
- R 5 and R 5 ′ are both hydrogen, in other embodiments of the invention, R 5 and R 5 ′ are both methyl, in other embodiments of the invention, R 5 is hydrogen and R 5 ′ is methyl.
- R 5 is hydrogen, R 5 ′ is methyl, X is O and Y is C ⁇ O.
- R 6 is hydrogen or C 1-6 -alkyl, preferably hydrogen.
- both R 7 and R 7 ′ are hydrogen.
- one of R 7 and R 7 ′ is hydrogen and the other is halo, halo-C 1-6 -alkyl, C 1-6 -alkyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, nitro, or cyano.
- R 7 and R 7 ′ are each independently hydrogen or halo.
- one of R 7 and R 7 ′ is hydrogen and the other is halo, preferably chloro.
- each of R 8 and R 8 ′ are independently hydrogen, halo, halo-C 1-6 -alkyl, C 1-6 -alkyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, nitro, or cyano.
- R 8 and R 8 ′ are each independently hydrogen, halo, or C 1-6 -alkoxy, preferably hydrogen, chloro, ethoxy or methoxy.
- R 7 and R 8 or R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety, wherein
- R 7 and R 8 are bound together to form a ring with the phenyl moiety as described above, and
- R 9 , R 8 ′ and R 7 ′ are hydrogen
- R 9 and R 7 ′ are hydrogen, and R 8 ′ is halo, preferably chloro, or
- R 9 and R 7 ′ are hydrogen, and R 8 ′ is C 1-6 -alkoxy, preferably ethoxy or methoxy.
- R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety as described above, and
- R 9 , R 8 and R 7 are hydrogen
- R 9 and R 7 are hydrogen, and R 8 is halo, preferably chloro, or
- R 9 and R 7 are hydrogen, and R 8 is C 1-6 -alkoxy, preferably ethoxy or methoxy.
- R 7 and R 8 are halo, preferably chloro, and R 9 , R 7 ′ and R 8 ′ are hydrogen.
- R 9 is hydrogen, halo, halo-C 1-6 -alkyl, C 1-6 -alkyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, nitro, or cyano.
- R 9 is hydrogen, halo, or C 1-6 -alkyl, preferably hydrogen, chloro or tert-butyl.
- R 8 and R 9 or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
- R 8 and R 9 are bound together to form a ring with the phenyl moiety as described above, and R 7 , R 8 ′ and R 7 ′ are hydrogen.
- R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety as described above, and R 7 , R 8 and R 7 ′ are hydrogen.
- R 8 and R 9 are halo, preferably chloro, and R 7 , R 7 ′ and R 8 ′ are hydrogen.
- R 8 ′ and R 9 are halo, preferably chloro, and R 7 , R 7 ′ and R 8 ′′ are hydrogen.
- R 9 is C 1-6 -alkyl or halo, preferably tert-butyl or chloro, and R 7 , R 7 ′, R 8 , and R 8 ′ are hydrogen.
- Preferred compounds of the invention are those of formula (I) wherein
- R 8 and R 9 are halo, or wherein R 8 and R 9 are bound together to form a ring with the phenyl moiety, wherein
- Preferred compounds of the invention are those of formula (I) wherein
- R 8 ′ and R 9 are halo, or wherein R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
- R 7 , R 7 ′, R 8 , R 8 ′ and R 9 are not simultaneously hydrogen.
- a certain embodiment of the invention relates to a compound of formula (I)
- R 5 and R 5 ′ are each independently hydrogen or methyl;
- R 6 is hydrogen or C 1-6 -alkyl;
- R 7 and R 7 ′ are each independently selected from
- R 8 and R 8 ′ are each independently selected from
- R 7 and R 8 or R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety, wherein
- R 8 and R 9 or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
- a certain embodiment of the invention relates to compounds of formula (I)
- R 5 and R 5 ′ are each independently hydrogen or methyl;
- R 6 is hydrogen or C 1-6 -alkyl;
- R 7 and R 7 ′ are each independently hydrogen or halo;
- R 8 and R 8 ′ are each independently hydrogen, halo, or C 1-6 -alkoxy;
- R 7 and R 8 or R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety, wherein
- the invention provides compounds of formula I wherein
- the invention provides compounds of formula I wherein
- the invention provides compounds of formula I wherein
- An embodiment of the invention relates to compounds of formula (I-a)
- R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-b)
- R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-c)
- R 1 to R 9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-d)
- R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-e)
- R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-f)
- R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-g)
- R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-h)
- R 1 to R 9 are as defined in any combination as described above.
- Any compound of formula (I-a) to (I-h) may be combined with any residue or combination of residues R 1 to R 9 as defined above.
- Preferred compounds are those of formula (I-a) to (I-f).
- Preferred compounds of the invention are those of the examples. More preferred are the following compounds:
- the invention also encompasses methods for the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders which comprises administering an effective amount of a compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h).
- the invention also encompasses a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may further comprise at least one pharmaceutically acceptable excipient.
- the compound of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
- the compound of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
- the compounds of the present invention exhibit V1a activity, which may be detected as described below:
- the human V1a receptor was cloned by RT-PCR from total human liver RNA.
- the coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence.
- Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
- the pellet was resuspended in 12.5 ml Lysis buffer+12.5 ml Sucrose 20% and homogenized using a Polytron for 1-2 min.
- the protein concentration was determined by the Bradford method, and aliquots were stored at ⁇ 80° C. until use.
- 60 mg Yttrium silicate SPA beads (Amersham) were mixed with an aliquot of membrane in binding buffer (50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM MgCl2) for 15 minutes with mixing.
- the present invention also provides pharmaceutical compositions containing compounds of the invention, such as compounds of formula (I), and (Ia) to (If), or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
- Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.
- the pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
- compositions of the invention in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier.
- suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic or organic carriers.
- Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatine capsules.
- Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
- Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
- Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
- Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
- compositions can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- a daily dosage of about 10 to 1000 mg per person of a compound of general formula (I) should be appropriate, although the above upper limit can also be exceeded when necessary.
- the active substance, lactose and corn starch can be firstly mixed in a mixer and then in a comminuting machine.
- the mixture the can be returned to the mixer, the talc can be added thereto and mixed thoroughly.
- the mixture can be filled by machine into hard gelatine capsules.
- the suppository mass can be melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C.
- the finely powdered active substance can be added thereto and stirred until it has dispersed completely.
- the mixture the can be poured into suppository moulds of suitable size, left to cool; the suppositories then can be removed from the moulds and packed individually in wax paper or metal foil.
- reaction mixture was added to a mixture of water (500 ml) and ether (300 mL).
- ether 300 mL
- the aqueous layer was extracted with ether (5 ⁇ 150 mL) and acidified with concentrated HCl (to pH 2-3) and extracted with ether (2 ⁇ 150 ml).
- the acidic solution was boiled for 1 h and then cooled to 0-5° C. and made alkaline (to pH 9-10) with aqueous NaOH.
- the cold solution was rapidly extracted with chloroform (5 ⁇ 300 mL).
- the combined chloroform extracts were washed with water (150 ml), dried over sodium sulfate and evaporated under reduced pressure.
- the residue was purified was purified by silica gel (100-200) column chromatography eluting with methanol in dichloromethane (0.5% to 2.5%) to afford 1 (4.2 g, 20%).
- the basic (aqueous) layer was extracted with ether (5 ⁇ 100 ml) and the aqueous layer was acidified with concentrated hydrochloric acid (pH 2-3) and extracted with ether.
- the aqueous solution was boiled for 1 h and was then cooled to 0-5° C. and made alkaline (pH 9-10) with cold aqueous sodium hydroxide.
- the cold solution was rapidly extracted with chloroform (5 ⁇ 200 ml).
- the combined chloroform extracts were washed with water, dried, concentrated to give light yellow solid which was purified over neutral alumina eluting with a gradient of 30-50% ethyl acetate-hexane to obtain 1.75 g (15%) of 9 as white solid.
- N-cyano lactone 5 (1.23 g, 5 mmol) was heated with ethylene glycol (5 ml) and sodium hydroxide (0.82 g, 20.5 mmol) for 15-20 min at 130° C. Most of the ethylene glycol was removed by distillation under high vacuum. The residual reaction mixture was diluted with water and extracted repeatedly with chloroform. The combined organics was dried and concentrated to give a semi solid material which was purified over Al2O3 column upon elution with 5-7% MeOH/CH 2 Cl 2 containing NH3 (aqueous) to yield 789 mg (60%) of CRI 1072 as pale yellow solid.
Abstract
The present invention is concerned with novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. The compounds of present invention are described with formula (I)
wherein R1 to R5, R5′, R7 to R9, R7′, R8′, X and Y are as defined in the specification.
Description
- This application claims the benefit of European Patent Application No. 06127086.4, filed Dec. 22, 2006, which is hereby incorporated by reference in its entirety.
- Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus. Three vasopressin receptors, all belonging to the class I G-protein coupled receptors, are known. The V1a receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis, the V1b or V3 receptor is expressed in the brain and pituitary gland, the V2 receptor is expressed in the kidney where it regulates water excretion and mediates the antidiuretic effects of vasopressin.
- In the periphery vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogenolysis and antidiuresis. In the brain vasopressin acts as a neuromodulator and is elevated in the amygdala during stress (Ebner, K., C. T. Wotjak, et al. (2002). “Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats.” Eur J Neurosci 15(2): 384-8). The V1a receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety. Indeed V1a knock-out mouse show a reduction in anxious behavior in the plus-maze, open field and light-dark box (Bielsky, I. F., S. B. Hu, et al. (2003). “Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice.” Neuropsychopharmacology). The downregulation of the V1a receptor using antisense oligonucleotide injection in the septum also causes a reduction in anxious behavior (Landgraf, R., R. Gerstberger, et al. (1995). “V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.” Regul Pept 59(2): 229-39).
- The V1a receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini, L. C. and M. Morris (1999). “Endogenous vasopressin modulates the cardiovascular responses to exercise.” Ann N Y Acad Sci 897: 198-211). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the V1a receptor improves hemodynamic parameters in myocardial infarcted rats (Van Kerckhoven, R., I. Lankhuizen, et al. (2002). “Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats.” Eur J Pharmacol 449(1-2): 135-41).
- The present invention provides novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.
- In particular, the present invention provides compounds of formula (I)
- wherein
-
- X is O and Y is C═O,
- X is O and Y is CH2,
- X is C═O and Y is NR6,
- X is CH2 and Y is O,
- X-Y is CH═CH,
- X-Y is CH2—CH2,
- X is C═O and Y is O, or
- X is CH2 and Y is NR6;
R1, R2, R3 and R4 are each independently
- hydrogen,
- halo,
- C1-6-alkyl, optionally substituted by OH,
- halo-C1-6-alkyl,
- C1-6-alkoxy, optionally substituted by OH, or
- halo-C1-6-alkoxy;
- R5 and R5′ are each independently hydrogen or methyl;
R6 is hydrogen or C1-6-alkyl;
R7, R7′, R8, R8′ and R9 are each independently selected from - hydrogen,
- halo,
- halo-C1-6-alkyl,
- C1-6-alkyl,
- C1-6-alkoxy,
- halo-C1-6-alkoxy,
- nitro, and
- cyano,
- or R7 and R8, R7′ and R8′, R8 and R9, or R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein
- —R7-R8— or —R7′-R8′— is
-
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- wherein R10 is hydrogen or C1-6-alkyl,
- —N(R11)—CH═CH— or —CH═CH—N(R11)—,
- wherein R11 is hydrogen or C1-6-alkyl,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —O—(CR16R16′)n—O—,
- wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl,
- —N(R17)—CH═N— or —N═CH—N(R17)—,
- wherein R17 is hydrogen or C1-6-alkyl, or
- —N(R18)—C(O)—CH2— or —CH2—C(O)—N(R18)—,
- wherein R18 is hydrogen or C1-6-alkyl,
or a pharmaceutically acceptable salt thereof.
- wherein R18 is hydrogen or C1-6-alkyl,
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- The compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the text or in the examples, or by methods known in the art.
- The compounds of formula (I) possess pharmaceutical activity, in particular they are modulators of V1a receptor activity. More particular, the compounds are antagonists of the V1a receptor. Such antagonists are useful as therapeutics in the conditions of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders. The preferred indications with regard to the present invention are the treatment of anxiety and depressive disorders.
- The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination. It must be noted that, as used in the specification and the appended claims, the singular forms “a”, “an,” and “the” include plural forms unless the context clearly dictates otherwise.
- In the present description, the term “alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated hydrocarbon radical. The term “C1-6-alkyl” denotes a saturated straight- or branched-chain hydrocarbon group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, the isomeric pentyls and the like. A preferred sub-group of C1-6-alkyl is C1-4-alkyl, i.e. with 1-4 carbon atoms.
- In the present invention, the term “alkylene” refers to a linear or branched saturated divalent hydrocarbon radical. In particular, “C1-6-alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g. methylene, ethylene, 2,2-dimethylethylene, n-propylene, 2-methylpropylene, and the like.
- In the present description, the term “alkoxy” and “C1-6-alkoxy” refers to the group R′—O—, wherein R′ is alkyl or C1-6-alkyl as defined above. Examples of alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy and the like. A preferred sub-group of C1-6-alkoxy, and still more preferred alkoxy groups are methoxy and/or ethoxy.
- In the present description, the term “thioalkyl” and “C1-6-thioalkyl” refers to the group R′—S—, wherein R′ is alkyl or C1-6-alkyl as defined above.
- The term “C1-6-hydroxyalkyl” or “C1-6-alkyl substituted by OH” denotes a C1-6-alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxyl group.
- The term “C1-6-cyanoalkyl” or “C1-6-alkyl substituted by CN” denotes a C1-6-alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a CN group.
- The term “halo” or “halogen” refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I) with fluorine, chlorine and bromine being preferred.
- The term “halo-C1-6-alkyl”” is synonymous with “C1-6-haloalkyl” or “C1-6-alkyl substituted by halo” and means a C1-6-alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro. Examples of halo-C1-6-alkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below. Among the preferred halo-C1-6-alkyl groups are difluoro- or trifluoro-methyl or -ethyl.
- The term “halo-C1-6-alkoxy” is synonymous with “C1-6-haloalkoxy” or “C1-6-alkoxy substituted by halo” and means a C1-6-alkoxy group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro. Among the preferred halogenated alkoxy groups are difluoro- or trifluoro-methoxy or -ethoxy.
- The term “C2-12-alkenyl”, alone or in combination, denotes a straight-chain or branched hydrocarbon residue of 2 to 12 carbon atoms comprising at least one double bond. A preferred sub-group of C2-12-alkenyl is C2-6-alkyenyl. Examples of the preferred alkenyl groups are ethenyl, propen-1-yl, propen-2-yl (allyl), buten-1-yl, buten-2-yl, buten-3-yl, penten-1-yl, penten-2-yl, penten-3-yl, penten-4-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, hexen-4-yl and hexen-5-yl, as well as those specifically illustrated by the examples herein below.
- The term “one or more” substituents preferably means one, two or three optional substituents per ring.
- “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
- The term “pharmaceutically acceptable acid addition salts” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
- “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
- The term “bound together to form a ring with the phenyl moiety” means that the residues of the phenyl ring, which are located in ortho-position to each other, may form an anellated ring to the phenyl moiety.
- The invention further comprises individual optical isomers of the compounds herein as well as racemic and non-racemic mixtures thereof.
- In detail, the present invention relates to compounds of formula (I)
- wherein
-
- X is O and Y is C═O,
- X is O and Y is CH2,
- X is C═O and Y is NR6,
- X is CH2 and Y is O,
- X-Y is CH═CH,
- X-Y is CH2—CH2,
- X is C═O and Y is O, or
- X is CH2 and Y is NR6;
R1, R2, R3 and R4 are each independently
- hydrogen,
- halo,
- C1-6-alkyl, optionally substituted by OH,
- halo-C1-6-alkyl,
- C1-6-alkoxy, optionally substituted by OH, or
- halo-C1-6-alkoxy;
- R5 and R5′ are each independently hydrogen or methyl;
R6 is hydrogen or C1-6-alkyl;
R7, R7′, R8, R8′, and R9 are each independently selected from - hydrogen,
- halo,
- halo-C1-6-alkyl,
- C1-6-alkyl,
- C1-6-alkoxy,
- halo-C1-6-alkoxy,
- nitro, and
- cyano,
- or R7 and R8, R7′ and R8′, R8 and R9, or R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein
- —R7-R8— or —R7′-R8′— is
-
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- wherein R10 is hydrogen or C1-6-alkyl,
- —N(R11)—CH═CH— or —CH═CH—N(R12)—,
- wherein R11 is hydrogen or C1-6-alkyl,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —O—(CR16R16′)n—O—,
- wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl,
- —N(R17)—CH═N— or —N═CH—N(R17)—,
- wherein R17 is hydrogen or C1-6-alkyl, or
- —N(R18)—C(O)—CH2— or —CH2—C(O)—N(R18)—,
- wherein R18 is hydrogen or C1-6-alkyl,
or a pharmaceutically acceptable salt thereof.
- wherein R18 is hydrogen or C1-6-alkyl,
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- In certain embodiments of the invention, R1, R2, R3 and R4 are each independently hydrogen, halo, C1-6-alkyl or C1-6-alkoxy, optionally substituted by OH.
- In certain embodiments of the invention, R1 is hydrogen or halo, preferably hydrogen or fluoro.
- In certain embodiments of the invention, R2 is hydrogen, halo or C1-6-alkoxy; preferably hydrogen, fluoro, bromo or methoxy.
- In certain embodiments of the invention, R3 is hydrogen, halo, or C1-6-alkoxy, optionally substituted by OH; preferably hydrogen, chloro, bromo, methoxy or —O(CH2)2OH.
- In certain embodiments of the invention, R4 is hydrogen or C1-6-alkyl; preferably hydrogen or methyl.
- In certain embodiments all R1 to R4 are hydrogen.
- In certain embodiments, one residue of R1 to R4 is halo and the others are hydrogen.
- In certain embodiments, one residue of R1 to R4 is C1-6-alkyl, preferably methyl, and the others are hydrogen.
- In certain embodiments, one residue of R1 to R4 is C1-6-alkoxy, optionally substituted by OH, preferably methoxy or —O(CH2)2OH, and the others are hydrogen.
- In certain embodiments of the invention, R5 and R5′ are both hydrogen, in other embodiments of the invention, R5 and R5′ are both methyl, in other embodiments of the invention, R5 is hydrogen and R5′ is methyl.
- In certain embodiments of the invention, R5 is hydrogen, R5′ is methyl, X is O and Y is C═O.
- In certain embodiments of the invention, R6 is hydrogen or C1-6-alkyl, preferably hydrogen.
- In certain embodiments of the invention, both R7 and R7′ are hydrogen.
- In certain embodiments of the invention, one of R7 and R7′ is hydrogen and the other is halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano. In certain embodiments of the invention, R7 and R7′ are each independently hydrogen or halo.
- In certain embodiments of the invention, one of R7 and R7′ is hydrogen and the other is halo, preferably chloro.
- In certain embodiments of the invention, each of R8 and R8′ are independently hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano.
- In certain embodiments of the invention, R8 and R8′ are each independently hydrogen, halo, or C1-6-alkoxy, preferably hydrogen, chloro, ethoxy or methoxy.
- In certain embodiments of the invention, R7 and R8 or R7′ and R8′ are bound together to form a ring with the phenyl moiety, wherein
- —R7-R8— or —R7′-R8′— is
-
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- wherein R10 is hydrogen or C1-6-alkyl,
- —N(R11)—CH═CH— or —CH═CH—N(R12)—,
- wherein R11 is hydrogen or C1-6-alkyl,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —O—(CR16R16′)n—O—,
- wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl, or
- —N(R17)—CH═N— or —N═CH—N(R17)—,
- wherein R17 is hydrogen or C1-6-alkyl.
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- In certain embodiments of the invention, R7 and R8 are bound together to form a ring with the phenyl moiety as described above, and
- R9, R8′ and R7′ are hydrogen,
- R9 and R7′ are hydrogen, and R8′ is halo, preferably chloro, or
- R9 and R7′ are hydrogen, and R8′ is C1-6-alkoxy, preferably ethoxy or methoxy.
- In certain embodiments of the invention, R7′ and R8′ are bound together to form a ring with the phenyl moiety as described above, and
- R9, R8 and R7 are hydrogen,
- R9 and R7 are hydrogen, and R8 is halo, preferably chloro, or
- R9 and R7 are hydrogen, and R8 is C1-6-alkoxy, preferably ethoxy or methoxy.
- In certain embodiments of the invention, R7 and R8 are halo, preferably chloro, and R9, R7′ and R8′ are hydrogen.
- In certain embodiments of the invention, R9 is hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano.
- In certain embodiments of the invention, R9 is hydrogen, halo, or C1-6-alkyl, preferably hydrogen, chloro or tert-butyl.
- In certain embodiments of the invention,
- R8 and R9 or R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein
- —R8-R9— or —R8′-R9′— is
-
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —N(R18)—C(O)—CH2— or —CH2—C(O)—N(R18)—,
- wherein R18 is hydrogen or C1-6-alkyl.
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- In certain embodiments of the invention, R8 and R9 are bound together to form a ring with the phenyl moiety as described above, and R7, R8′ and R7′ are hydrogen.
- In certain embodiments of the invention, R8′ and R9 are bound together to form a ring with the phenyl moiety as described above, and R7, R8 and R7′ are hydrogen.
- In certain embodiments of the invention, R8 and R9 are halo, preferably chloro, and R7, R7′ and R8′ are hydrogen.
- In certain embodiments of the invention, R8′ and R9 are halo, preferably chloro, and R7, R7′ and R8″ are hydrogen.
- In certain embodiments of the invention, R9 is C1-6-alkyl or halo, preferably tert-butyl or chloro, and R7, R7′, R8, and R8′ are hydrogen.
- Preferred compounds of the invention are those of formula (I) wherein
- R8 and R9 are halo, or wherein
R8 and R9 are bound together to form a ring with the phenyl moiety, wherein - —R8-R9— is
-
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
and R7, R7′ and R8′ are hydrogen.
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- Preferred compounds of the invention are those of formula (I) wherein
- R8′ and R9 are halo, or wherein
R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein - —R8′-R9— is
-
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
and R7, R7′ and R8 are hydrogen.
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- Preferably, R7, R7′, R8, R8′ and R9 are not simultaneously hydrogen.
- A certain embodiment of the invention relates to a compound of formula (I)
- wherein
-
- X is O and Y is C═O,
- X is O and Y is CH2,
- X is C═O and Y is NR6,
- X is CH2 and Y is O; or
- X-Y is CH═CH, or
- X-Y is CH2—CH2, or
- X is C═O and Y is O, or
- X is CH2 and Y is NR6;
R1, R2, R3 and R4 are each independently
- hydrogen,
- halo,
- C1-6-alkyl, optionally substituted by OH,
- halo-C1-6-alkyl,
- C1-6-alkoxy, optionally substituted by OH, or
- halo-C1-6-alkoxy;
- R5 and R5′ are each independently hydrogen or methyl;
R6 is hydrogen or C1-6-alkyl;
R7 and R7′ are each independently selected from - hydrogen,
- halo,
- halo-C1-6-alkyl,
- C1-6-alkyl,
- C1-6-alkoxy,
- halo-C1-6-alkoxy,
- nitro, and
- cyano;
- R8 and R8′ are each independently selected from
- hydrogen,
- halo,
- C1-6-alkoxy,
- halo-C1-6-alkyl,
- C1-6-alkyl,
- halo-C1-6-alkoxy,
- nitro, and
- cyano;
- R7 and R8 or R7′ and R8′ are bound together to form a ring with the phenyl moiety, wherein
- —R7-R8— or —R7′-R8′— is
-
- —N(R10)—N═CH—, or —CH═N—N(R10)—,
- wherein R10 is hydrogen or C1-6-alkyl,
- —N(R11)—CH═CH—, or —CH═CH—N(R11)—,
- wherein R11 is hydrogen or C1-6-alkyl,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —O—(CR16R16)n—O—,
- wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl,
- —N(R17)—CH═N—, or —N═CH—N(R17)—,
- wherein R17 is hydrogen or C1-6-alkyl,
R9 is hydrogen,
- wherein R17 is hydrogen or C1-6-alkyl,
- —N(R10)—N═CH—, or —CH═N—N(R10)—,
- halo,
- C1-6-alkyl,
- halo-C1-6-alkyl,
- C1-6-alkoxy,
- halo-C1-6-alkoxy,
- nitro, or
- cyano;
- R8 and R9 or R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein
- —R8-R9— or —R8′-R9— is
-
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —N(R18)—C(O)—CH2—, or —CH2—C(O)—N(R18)—,
- wherein R18 is hydrogen or C1-6-alkyl,
or a pharmaceutically acceptable salt thereof.
- wherein R18 is hydrogen or C1-6-alkyl,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- A certain embodiment of the invention relates to compounds of formula (I)
- wherein
-
- X is O and Y is C═O,
- X is O and Y is CH2,
- X is C═O and Y is NR6,
- X is CH2 and Y is O,
- X-Y is CH═CH,
- X-Y is CH2—CH2,
- X is C═O and Y is O, or
- X is CH2 and Y is NR6;
R1, R2, R3 and R4 are each independently
- hydrogen,
- halo, or
- C1-6-alkoxy, optionally substituted by OH,
- R5 and R5′ are each independently hydrogen or methyl;
R6 is hydrogen or C1-6-alkyl;
R7 and R7′ are each independently hydrogen or halo;
R8 and R8′ are each independently hydrogen, halo, or C1-6-alkoxy;
R7 and R8 or R7′ and R8′ are bound together to form a ring with the phenyl moiety, wherein - —R7-R8— or —R7′-R8′— is
-
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- wherein R10 is hydrogen or C1-6-alkyl,
- —N(R11)—CH═CH— or —CH═CH—N(R11)—,
- wherein R11 is hydrogen or C1-6-alkyl,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13 R14 and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —O—(CR16R16′)n—O—,
- wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl,
- —N(R17)—CH═N— or —N═CH—N(R17)—,
- wherein R17 is hydrogen or C1-6-alkyl,
R9 is hydrogen, halo, or C1-6-alkyl;
R8 and R9 or R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein
- wherein R17 is hydrogen or C1-6-alkyl,
- —N(R10)—N═CH— or —CH═N—N(R10)—,
- —R8-R9— or —R8′-R9— is
-
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
- —N(R18)—C(O)—CH2— or —CH2—C(O)—N(R18)—,
- wherein R18 is hydrogen or C1-6-alkyl,
or a pharmaceutically acceptable salt thereof.
- wherein R18 is hydrogen or C1-6-alkyl,
- —C(R12)═C(R13)—C(R14)═C(R15)—,
- In one embodiment, the invention provides compounds of formula I wherein
-
- X is O and Y is C═O,
- X is O and Y is CH2,
- X is CH2 and Y is O, or
- X is C═O and Y is O.
- In one embodiment, the invention provides compounds of formula I wherein
-
- X is C═O and Y is NR6, or
- X is CH2 and Y is NR6.
- In one embodiment, the invention provides compounds of formula I wherein
-
- X is C═O and Y is NR6, or
- X is CH2 and Y is NR6.
- An embodiment of the invention relates to compounds of formula (I-a)
- wherein R1 to R5′ and R7 to R9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-b)
- wherein R1 to R5′ and R7 to R9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-c)
- wherein R1 to R9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-d)
- wherein R1 to R5′ and R7 to R9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-e)
- wherein R1 to R5′ and R7 to R9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-f)
- wherein R1 to R5′ and R7 to R9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-g)
- wherein R1 to R5′ and R7 to R9 are as defined in any combination as described above.
- An embodiment of the invention relates to compounds of formula (I-h)
- wherein R1 to R9 are as defined in any combination as described above.
- Any compound of formula (I-a) to (I-h) may be combined with any residue or combination of residues R1 to R9 as defined above.
- Preferred compounds are those of formula (I-a) to (I-f).
- Preferred compounds of the invention are those of the examples. More preferred are the following compounds:
- 6-Methoxy-1′-(2-naphthoyl)-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one,
- 1′-(3,4-Dichlorobenzoyl)-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one,
- 1′-(3,4-Dichlorobenzoyl)-6-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one,
- 1′-(3,4-Dichlorobenzoyl)-5-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one,
- 1′-(3,4-Dichlorobenzoyl)-5-fluoro-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one,
- 1′-(3,4-Dichlorobenzoyl)-6-(2-hydroxyethoxy)-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one,
- 1′-(4-tert-Butylbenzoyl)-3H-spiro[2-benzofuran-1,4′-piperidine],
- 1′-[(5-Methoxy-1H-indol-7-yl)carbonyl]-3H-spiro[2-benzofuran-1,4′-piperidine],
- 5-Bromo-1′-(2-naphthoyl)spiro[indole-3,4′-piperidin]-2(1H)-one,
- 1′-(2-Naphthoyl)spiro[indene-1,4′-piperidine], and
- 1′-(3,4-Dichlorobenzoyl)-2,3-dihydrospiro[indene-1,4′-piperidine].
- The invention also encompasses methods for the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders which comprises administering an effective amount of a compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h).
- The invention also encompasses a pharmaceutical composition comprising a compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) and a pharmaceutically acceptable carrier. The pharmaceutical composition may further comprise at least one pharmaceutically acceptable excipient.
- In a certain embodiment, the compound of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
- with an acid chloride of formula (III-b)
- to obtain the compound according to formula (I) wherein R1 to R10 and X and Y are as defined above.
- In a certain embodiment, the compound of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
- with an acid of formula (III-a)
- to obtain the compound of formula (I) wherein R1 to R10 and X and Y are as defined above.
- The synthesis of compounds of general formula (I) will be described in more detail below and in the examples.
- The compounds of the present invention exhibit V1a activity, which may be detected as described below:
- The human V1a receptor was cloned by RT-PCR from total human liver RNA. The coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence. To demonstrate the affinity of the compounds from the present invention to the human V1a receptor binding studies were performed. Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
- 50 g of cells were resuspended in 30 ml freshly prepared ice cold Lysis buffer (50 mM HEPES, 1 mM EDTA, 10 mM MgCl2 adjusted to pH=7.4+complete cocktail of protease inhibitor (Roche Diagnostics)); homogenized with Polytron for 1 min; and sonicated on ice for 2×2 minutes at 80% intensity (Vibracell sonicator). The preparation was centrifuged 20 min at 500 g at 4° C., the pellet was discarded and the supernatant centrifuged 1 hour at 43′000 g at 4° C. (19′000 rpm). The pellet was resuspended in 12.5 ml Lysis buffer+12.5 ml Sucrose 20% and homogenized using a Polytron for 1-2 min. The protein concentration was determined by the Bradford method, and aliquots were stored at −80° C. until use. For binding studies 60 mg Yttrium silicate SPA beads (Amersham) were mixed with an aliquot of membrane in binding buffer (50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM MgCl2) for 15 minutes with mixing. 50 ul of bead/membrane mixture was then added to each well of a 96 well plate, followed by 50 ul of 4 nM 3H-Vasopressin (American Radiolabeled Chemicals). For total binding measurement 100 ul of binding buffer were added to the respective wells, for non-specific binding 100 ul of 8.4 mM cold vasopressin and for compound testing 100 ul of a serial dilution of each compound in 2% DMSO. The plate was incubated 1 h at room temperature, centrifuged 1 min at 1000 g and counted on a Packard Top-Count. Non-specific binding counts were subtracted from each well and data was normalized to the maximum specific binding set at 100%. To calculate an IC 50 the curve was fitted using a non-linear regression model (XLfit), and the Ki was calculated using the Cheng-Prussoff equation.
-
Ex pKi hV1a 1 8.08 6 7.72 7 7.54 9 7.32 11 7.53 12 7.66 25 7.2 27 7.3 33 6.96 36 7.05 42 6.95 - The present invention also provides pharmaceutical compositions containing compounds of the invention, such as compounds of formula (I), and (Ia) to (If), or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
- The pharmaceutical compositions of the invention, in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic or organic carriers.
- Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatine capsules. Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc. Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc. Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc. Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
- Moreover, the pharmaceutical compositions can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- The dosage at which a compound of the invention can be administered can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula (I) should be appropriate, although the above upper limit can also be exceeded when necessary.
- The following Examples illustrate the present invention without limiting it. All temperatures are given in degrees Celsius.
- Tablets of the following composition can be manufactured in the usual manner:
-
mg/tablet Active substance 5 Lactose 45 Corn starch 15 Microcrystalline cellulose 34 Magnesium stearate 1 Tablet weight 100 - Capsules of the following composition are manufactured:
-
mg/capsule Active substance 10 Lactose 155 Corn starch 30 Talc 5 Capsule fill weight 200 - The active substance, lactose and corn starch can be firstly mixed in a mixer and then in a comminuting machine. The mixture the can be returned to the mixer, the talc can be added thereto and mixed thoroughly. The mixture can be filled by machine into hard gelatine capsules.
- Suppositories of the following composition can be manufactured:
-
mg/supp. Active substance 15 Suppository mass 1285 Total 1300 - The suppository mass can be melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C.
- Thereupon, the finely powdered active substance can be added thereto and stirred until it has dispersed completely. The mixture the can be poured into suppository moulds of suitable size, left to cool; the suppositories then can be removed from the moulds and packed individually in wax paper or metal foil.
- In the following, the synthesis of compounds of formula (I) is further exemplified: The following general scheme A is an example of the preparation of the compounds of the invention according to general procedure 1:
- General Procedure 1—Amide Coupling with Acid Chlorides:
- A solution of the amine (1 eq), the acid chloride (1 eq) and DIPEA (1.5 eq) in DMF is stirred at RT for 14 h. The mixture is concentrated and purified by preparative HPLC to yield the desired product.
- The following general scheme B is an example of the preparation of the compounds of the invention according to general procedure 2:
- General Procedure 2—Amide Coupling with Carboxylic Acids:
- A solution of the acid (1 eq) and HATU (1 eq) in DMF is shaken for 30 min at RT and then a solution of the amine (1 eq) and DIPEA (2 eq) in DMF is added and the mixture shaken at RT for 2 h. The mixture is concentrated and purified by preparative HPLC to yield the desired product.
-
- Amide coupling according to general procedure I:
- Amine: 6-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid chloride: Naphthalene-2-carbonyl chloride
- ES-MS m/e (%): 388.4 (M+H+).
-
- Amide coupling according to general procedure I:
- Amine: 6-chloro-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid chloride: 4-tert-Butyl-benzoyl chloride
- ES-MS m/e (%): 398.4 (M+H+).
-
- Amide coupling according to general procedure I:
- Amine: rac-(1R,3′S)-3′-methyl-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in WO 9929696)
- Acid chloride: 4-tert-Butyl-benzoyl chloride
- ES-MS m/e (%): 378.5 (M+H+).
-
- Amide coupling according to general procedure I:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in Journal of Organic Chemistry (1976), 41(15), 2628-33)
- Acid chloride: 4-tert-Butyl-benzoyl chloride
- ES-MS m/e (%): 364.5 (M+H+).
-
- Amide coupling according to general procedure I:
- Amine: 5-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid chloride: Naphthalene-2-carbonyl chloride
- ES-MS m/e (%): 388.5 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in Journal of Organic Chemistry (1976), 41(15), 2628-33)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 376.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 6-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 406.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 6-chloro-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 410.3 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 5-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 406.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 5-bromo-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described herein)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 456.3 (M+H+).
- The synthesis of 5-bromo-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one is described below (3):
- Butyllithium (97.2 ml of 1.47 M solution in hexane, 143 mmol) was added dropwise to a solution of 2,5-Dibromo-benzoic acid (20 g, 72 mmol) in dry THF (300 ml) at −78° C. over a period of 3.5 h under a nitrogen atmosphere. The reaction mixture was stirred at −78° C. for 2 h. A solution of N-methyl piperidone (11.31 g, 99 mmol) in hexane (40 mL) was added dropwise during 30 min to the reaction mixture at 78° C. The reaction mixture was allowed to come to room temperature and stirring was continued for overnight. The reaction mixture was added to a mixture of water (500 ml) and ether (300 mL). The aqueous layer was extracted with ether (5×150 mL) and acidified with concentrated HCl (to pH 2-3) and extracted with ether (2×150 ml).
- The acidic solution was boiled for 1 h and then cooled to 0-5° C. and made alkaline (to pH 9-10) with aqueous NaOH. The cold solution was rapidly extracted with chloroform (5×300 mL). The combined chloroform extracts were washed with water (150 ml), dried over sodium sulfate and evaporated under reduced pressure. The residue was purified was purified by silica gel (100-200) column chromatography eluting with methanol in dichloromethane (0.5% to 2.5%) to afford 1 (4.2 g, 20%). 1H-NMR (400 MHz, CDCl3): δ 1.71 (d, J=14.2 Hz, 2H), 2.15-2.24 (m, 2H), 2.37 (s, 3H), 2.45-2.52 (m, 2H), 2.83-2.87 (m, 2H), 7.26 (d, J=8.25 Hz, 1H), 7.75 (dd, J=7.8, 1.7 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ 35.95, 46.05, 51.42, 84.00, 122.54, 122.97, 127.52, 128.64, 137.06, 152.24, 167.77.
- A solution of 1 (3.0 g, 10 mmol) in chloroform (50 ml) was added dropwise to a stirred boiling solution of cyanogens bromide (12.16 g, 120 mmol) in chloroform (100 ml) under a nitrogen atmosphere and the resulting solution was refluxed for overnight. The reaction mixture was cooled and washed with 25 mL of 5% HCl and then with 20 ml of water. The organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (100-200) eluting with methanol in dichloromethane (0.5% to 1.0%) to get the pure product (1.6 g, 51%). 1H-NMR (400 MHz, CDCl3): δ 1.72 (d, J=14.2 Hz, 2H), 2.24-2.32 (m, 2H), 3.37-3.59 (m, 4H), 7.32 (d, J=8.2 Hz, 1H), 7.83 (dd, J=8.0, 1.7 Hz, 1H), 8.03 (d, J=1.7 Hz, 1H).
- A mixture of 2 (1.0 g, 3.2 mmol) and 20% HCl (12 ml) was heated under reflux under a nitrogen atmosphere for 6 h. The reaction mixture was cooled to 0-5° C. and pH was adjusted to 9-10 with aqueous NaOH solution and rapidly extracted with chloroform (3×50 ml). The combined extracts were washed with water, the organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was washed with distilled hexane and dried under high vacuum to get the pure product (0.64 g, 70%). IR (KBr) 3333.84, 290.53, 283525, 2811.07, 2749.38, 1756.04, 1470.28, 1415.14, 1271.03, 1196.28, 1083.84, 929.07, 831.50, 792.35, 734.78, 691.24, 548.46, 534.50 cm-1. 1H-NMR (400 MHz, CDCl3): δ 1.66-1.72 (m, 2H), 2.02-2.09 (m, 2H), 3.07-3.18 (m, 4H), 7.29 (d, J=7.8 Hz, 1H), 7.77 (dd, J=7.8, 1.7 Hz, 1H), 7.99 (d, J=1.7 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ 6.33, 42.49, 85.23, 122.61, 122.93, 127.39, 128.64, 137.07, 152.44, 167.91. FIA-MS: 282.1 and 284.1; C12H1279BrNO2 [MH+] requires 282.1. mp: 162-163° C.
-
- Amide coupling according to general procedure 2:
- Amine: 5-fluoro-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in WO 2001014376)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 394.3 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 6-(2-hydroxyethoxy)-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in WO 2001014376)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 436.4 (M+H+).
-
- To a solution of the substituted 2-bromo-4-fluoro-benzoic acid (10.9 g, 50 mmol) in dry THF (200 ml) at −78° C. n-butyllithium (1.6 M in hexanes) (100 mmol) was added drop wise (3 h) and the resulting solution was stirred for an additional 2 h at the same temperature. Freshly distilled N-methyl 4-piperidone 6 (7.91 g, 70 mmol) in dry hexane (25 ml) was added over 30 min at the same temperature. The mixture was then allowed to stir at rt and was finally added to ether (200 ml) and water (300 ml). The basic (aqueous) layer was extracted with ether (5×100 ml) and the aqueous layer was acidified with concentrated hydrochloric acid (pH 2-3) and extracted with ether. The aqueous solution was boiled for 1 h and was then cooled to 0-5° C. and made alkaline (pH 9-10) with cold aqueous sodium hydroxide. The cold solution was rapidly extracted with chloroform (5×200 ml). The combined chloroform extracts were washed with water, dried, concentrated to give light yellow solid which was purified over neutral alumina eluting with a gradient of 30-50% ethyl acetate-hexane to obtain 1.75 g (15%) of 9 as white solid. 1H-NMR (CDCl3, 400 MHz): 1.68-1.75 (m, 2H), 2.18-2.19 (m, 1H), 2.38 (s, 3H), 2.44-2.52 (m, 2H), 2.68-2.84 (m, 2H), 2.84-2.85 (m, 1H), 7.02-7.05 (m, 1H), 7.19-7.22 (m, 1H), 7.84-7.87 (m, 1H); FIA-MS: 236 (M+1).
- To a solution of the N-methylated lactone 9 (1.17 g, 5 mmol) in dry chloroform (10 ml) was added cyanogenbromide (60 mnol) and the resulting solution was refluxed for 36 h. The reaction mixture was extracted with 5% HCl (5 ml) and then with water (2.5 ml). The chloroform solution was dried (anhydrous MgSO4) and concentrated to give a pale yellow solid which was chromatographed over SiO2 eluting with 1% MeOH—CH2Cl2 to give 858 mg (70%) 5 as white solid. 1H-NMR (CDCl3, 400 MHz): 1.72-1.76 (m, 2H), 2.22-2.30 (m, 1H), 3.48-3.60 (m, 4H), 7.09-7.11 (m, 1H), 7.11-7.28 (m, 1H), 7.89-7.92 (m, 1H); IR (KBr): 3492, 3043, 2216, 1760, 1602, 1478 cm-1.
- N-cyano lactone 5 (1.23 g, 5 mmol) was heated with ethylene glycol (5 ml) and sodium hydroxide (0.82 g, 20.5 mmol) for 15-20 min at 130° C. Most of the ethylene glycol was removed by distillation under high vacuum. The residual reaction mixture was diluted with water and extracted repeatedly with chloroform. The combined organics was dried and concentrated to give a semi solid material which was purified over Al2O3 column upon elution with 5-7% MeOH/CH2Cl2 containing NH3 (aqueous) to yield 789 mg (60%) of CRI 1072 as pale yellow solid. 1H-NMR (d6-DMSO, 400 MHz): 1.47-1.50 (m, 2H), 2.03-2.10 (m, 2H0, 2.79-2.85 (m, 2H), 2.95-2.97 (m, 2H), 3.73-3.76 (m, 2H), 4.12-4.14 (m, 2H), 7.09 (d, J=8.4 Hz, 1H), 7.20 (s, 1H), 7.69 (d, J=8.4 Hz, 1H); 13C-NMR (d6-DMSO, 100 MHz): 35.9, 42.3, 59.3, 70.4, 84.6, 106.4, 116.6, 117.0, 126.8, 156.9, 163.9, 168.5; FIA-MS: 264.3 (M+1).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in Journal of Organic Chemistry (1976), 41(15), 2628-33)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 376.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 6-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 406.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 6-chloro-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 410.2 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 5-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 406.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 5-fluoro-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in WO 2001014376)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 394.3 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 6-(2-hydroxyethoxy)-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described herein)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 436.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in Journal of Organic Chemistry (1976), 41(15), 2628-33)
- Acid: 5-Chloro-1H-indazole-7-carboxylic acid (described in WO 2006013048)
- ES-MS m/e (%): 382.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 6-methoxy-3H-spiro[2-benzofuran-1,4′-piperidin]-3-one (described in EP 722941)
- Acid: 5-Chloro-1H-indazole-7-carboxylic acid (described in WO 2006013048)
- ES-MS m/e (%): 412.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: Naphthalene-1-carboxylic acid
- ES-MS m/e (%): 344.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 4-fluoro-3H-spiro[2-benzofuran-1,4′-piperidine]
- (prepared according to Journal of Medicinal Chemistry (1995), 38(11), 2009-17)
- Acid: Naphthalene-1-carboxylic acid
- ES-MS m/e (%): 362.3 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 4-fluoro-3H-spiro[2-benzofuran-1,4′-piperidine] (prepared according to Journal of Medicinal Chemistry (1995), 38(11), 2009-17)
- Acid: 2-Ethoxynaphthalene-1-carboxylic acid (CAS 2224-00-2)
- ES-MS m/e (%): 406.5 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: 2-Ethoxynaphthalene-1-carboxylic acid (CA 2224-00-2)
- ES-MS m/e (%): 388.3 (M+H+).
-
- Amide coupling according to general procedure 1:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: 4-tert-Butyl-benzoyl chloride
- ES-MS m/e (%): 350.5 (M+H+).
-
- Amide coupling according to general procedure 1:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: 2,2-Difluoro-benzo[1,3]dioxole-4-carbonyl chloride (CAS 143096-86-0)
- ES-MS m/e (%): 374.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: 5-Methoxy-1H-indole-7-carboxylic acid (prepared herein)
- ES-MS m/e (%): 363.5 (M+H+).
-
- A solution of 7-Bromo-5-methoxy-1H-indole (described in WO 2002028861) in THF was treated with 2 eq. of a solution of n-BuLi in n-hexane (1.6M) at 5° and after 30 min at this temperature was cooled to −75°. Dry ice (excess) was added and after 15 mins the mixture was quenched with H2O and washed with EtOAc. After acidification of the aqueous layer and extraction into CH2Cl2, evaporation gave the desired product.
- ES-MS m/e (%): 192.1 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: 3H-Benzoimidazole-4-carboxylic acid (CAS 46006-36-4)
- ES-MS m/e (%): 334.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: 1H-Indole-7-carboxylic acid (CAS 1670-83-3)
- ES-MS m/e (%): 333.5 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: Benzo[1,3]dioxole-4-carboxylic acid (CAS 5768-39-8)
- ES-MS m/e (%): 338.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 3H-spiro[2-benzofuran-1,4′-piperidine] (CAS 38309-60-3)
- Acid: 3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid (described in EP 344634)
- ES-MS m/e (%): 377.5 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 5-bromo-spiro[indole-3,4′-piperidin]-2(1H)-one (preparation described herein)
- Acid: 4-tert-Butyl-benzoic acid
- ES-MS m/e (%): 441.5 (M+H+).
-
- Formic acid (10.0 g; 0.2 mol) and 37% formaldehyde (20 ml) were mixed in a 250 ml round-bottom flask equipped with reflux condenser. 1,5-Dichloro-3-azapentane, hydrochloride (17.0 g; 0.1 mol) was added and the solution was heated with magnetic stirring at 100° C. After 3 h the temperature was increased to 120° C. for 20 min and finally allowed to cool to room temperature before the solvent was evaporated in vacuo to afford 8 as white solid in quantitative yield. 1HNMR (CD3OD, 400 MHz) δ 3.0 (s, 3H); 3.45 (br s, 2H); 3.62 (br s, 2H); 4.07 (br s, 4H).
- A solution of oxindole 9 (6.25 g, 47 mmol) in THF (500 ml) was cooled to −78° C. and to it a solution of sodium hexamethyldisilazide (43 g, 235 mmol) in THF (300 ml) was added drop wise under N2 atmosphere. After stirring at −78° C. for 45 min, N-methylbis (2-chloromethyl) amine hydrochloride (9 g, 47 mmol) was added, as a solid. The reaction mixture was stirred at −78° C. for 1 h and at room temperature for 24 h. After quenching with H2O (90 ml), the mixture was extracted with ethyl acetate (3×100 ml). The organic extracts were washed with brine (25 ml), dried and the solvent removed in vacuo. Silica gel chromatography (5-50% MeOH/CH2Cl2, gradient) gave 6 g (57%) of 10 as a solid. 1HNMR (CD3OD, 400 MHz) δ 1.84 (m, 2H); 2.51 (m, 2H); 2.62 (s, 3H); 3.02 (m, 2H); 3.37 (m, 2H); 6.82 (d, 1H, J=7.68 Hz); 6.94 (t, 1H, J=7.58 Hz); 7.12 (t, 1H, J=7.7 Hz); 7.26 (d, 1H, J=9 Hz); 9.27 (br s, 1H).
- A solution of 1′-(methyl)spiro[indole-3,4′-piperidin]-2(1H)-one (6.3 g, 29.1 mmol) in CH3CN (100 ml) and MeOH (5 ml) was cooled to −5° C. and NBS (7.8 g, 44 mmol) was slowly added with stirring. The reaction mixture was stirred for 3.5 h at 0° C. Solvent was removed by vacuo. The residue was purified by silica gel chromatography (2-20% MeOH/CH2Cl2) to give 6 g as a solid. The solid compound was dissolved in ethyl acetate (600 ml) and washed with saturated aqueous NaHCO3 solution, dried (Na2SO4). Evaporation of the solvent in vacuo gave 4.2 g (47%) of 11. 1HNMR (CD3OD, 400 MHz) δ 7.51 (d, J=1.8 Hz, 1H), 7.35 (dd, J=1.9 and 8.2 Hz, 1H), 6.81 (d, J=8.2 Hz, 1H), 2.93 (m, 2H), 2.67 (m, 2H), 2.41 (s, 3H), 1.86 (m, 4H).
- 5-bromo-1′-(methyl)spiro[indole-3,4′-piperidin]-2(1H)-one 11 (4.6 g, 15.6 mmol) was dissolved in chloroform (700 ml) and treated with CNBr (22 g, 209.5 mmol) at room temperature. The mixture was heated to reflux for 24 h. The reaction mixture was cooled, diluted with methylene chloride (300 ml) and washed with 10% aqueous K2CO3 solution (2×100 ml). After the mixture was dried (Na2SO4) and concentrated, the residue was purified by silica gel chromatography (0-5% MeOH/CH2Cl2) to gave 7 as a solid 3.9 g (82%). 1HNMR (CDCl3, 400 MHz) δ 7.52 (d, J=1.8 Hz, 1H), 7.37 (dd, J=1.8 and 8.2 Hz, 1H), 6.82 (d, J=8.2 Hz, 1H), 3.83 (m, 2H), 3.41 (m, 2H), 2.00 (m, 2H), 1.86 (m, 2H).
- 5-Bromo-1,2-dihydro-2-oxospiro[3H-indole-3,4′-piperidine]-1′-cyano 12 (3.3 g, 10.8 mmol) was suspended in ethylene glycol (10 ml). The mixture was treated in NaOH (1.8 g, 45 mmol) and heated to 130° C. for 15 min. It was diluted with methylene chloride (500 ml) and washed with 10% aqueous K2CO3 (2×100 m). The organic layer was dried (Na2SO4) and concentrated and residue purified by silica gel chromatography (30% MeOH/CH2Cl2) to gave 13 as a light ceramic white solid 1.8 g (60%), mp 256-258° C. 1HNMR (DMSO-d6, 400 MHz) δ 10.6 (br s, 1H, NH), 7.57 (d, J=1.84 Hz, 1H), 7.36 (d, J=8.2 Hz, 1H), 6.79 (d, J=8.2 Hz, 1H), 4.05 (br s, 1H, NH), 3.06 (m, 2H), 2.84 (m, 2H), 1.64 (m, 2H), 1.55 (m, 2H), 13C NMR (DMSO-d6, 100 MHz) δ 180.93, 140.64, 137.98, 130.42, 126.75, 113.20, 111.45, 46.24, 40.92, 32.94. Anal. Calcd for C12H13BrN2O: C, 51.26; H, 4.66; N, 9.9. Found: C, 50.87; H, 4.91; N, 9.67.
-
- Amide coupling according to general procedure 2:
- Amine: 5-bromo-spiro[indole-3,4′-piperidin]-2(1H)-one (preparation described herein)
- Acid: Naphthalene-2-carboxylic acid
- ES-MS m/e (%): 435.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 4-methylspiro[indole-3,4′-piperidin]-2(1H)-one (preparation in analogy to 5-bromospiro[indole-3,4′-piperidin]-2(1H)-one starting from 1,5-Dichloro-3-methyl-3-azapentane, hydrochloride
- Acid: 4-Chloro-benzoic acid
- ES-MS m/e (%): 355.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: Spiro[1-benzofuran-3,4′-piperidine] (CAS 38309-60-3)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 362.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: Spiro[indene-1,4′-piperidine] (CAS 33042-66-9)
- Acid: Naphthalene-2-carboxylic acid
- ES-MS m/e (%): 340.5 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: Spiro[indene-1,4′-piperidine] (CAS 33042-66-9)
- Acid: 4-tert-Butyl-benzoic acid
- ES-MS m/e (%): 346.5 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: Spiro[indene-1,4′-piperidine] (CAS 33042-66-9)
- Acid: 2,2-Difluoro-benzo[1,3]dioxole-4-carbonyl chloride (CAS 143096-86-0)
- ES-MS m/e (%): 370.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: Spiro[indene-1,4′-piperidine] (CAS 33042-66-9)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 358.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: Spiro[indene-1,4′-piperidine] (CAS 33042-66-9)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 358.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: Spiro[indene-1,4′-piperidine] (CAS 33042-66-9)
- Acid: 5-Chloro-1H-indazole-7-carboxylic acid (described in WO 2006013048)
- ES-MS m/e (%): 364.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 2,3-Dihydrospiro[indene-1,4′-piperidine] (CAS 428-38-6)
- Acid: 3,4-Dichloro-benzoic acid
- ES-MS m/e (%): 360.4 (M+H+).
-
- Amide coupling according to general procedure 2:
- Amine: 2,3-Dihydrospiro[indene-1,4′-piperidine] (CAS 428-38-6)
- Acid: 2,3-Dichloro-benzoic acid
- ES-MS m/e (%): 360.4 (M+H+).
Claims (23)
1. A compound of formula (I)
wherein
X is C═O and Y is NR6, or
X is CH2 and Y is NR6;
R1, R2, R3 and R4 are each independently
hydrogen,
halo,
C1-6-alkyl, optionally substituted by OH,
halo-C1-6-alkyl,
C1-6-alkoxy, optionally substituted by OH, or
halo-C1-6-alkoxy;
R5 and R5′ are each independently hydrogen or methyl;
R6 is hydrogen or C1-6-alkyl;
R7, R7′ R8, R8′, and R9 are each independently selected from
hydrogen,
halo,
halo-C1-6-alkyl,
C1-6-alkyl,
C1-6-alkoxy,
halo-C1-6-alkoxy,
nitro, and
cyano,
or R7 and R8, R7′ and R8′, R8 and R9, or R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein
—R7-R8— or —R7′-R8′— is
—N(R10)—N═CH—, or —CH═N—N(R10)—,
wherein R10 is hydrogen or C1-6-alkyl,
—N(R11)—CH═CH—, or —CH═CH—N(R12)—,
wherein R11 is hydrogen or C1-6-alkyl,
—C(R12)═C(R13)—C(R14)═C(R15)—,
wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
—O—(CR16R16′)n—O—,
wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl,
—N(R17)—CH═N—, or —N═CH—N(R17)—,
wherein R17 is hydrogen or C1-6-alkyl, or
—N(R18)—C(O)—CH2—, or —CH2—C(O)—N(R18)—,
wherein R18 is hydrogen or C1-6-alkyl,
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein
R1, R2, R3 and R4 are each independently
hydrogen,
halo,
C1-6-alkyl, or
C1-6-alkoxy, optionally substituted by OH.
5. The compound of claim 1 wherein R1 is hydrogen or halo.
6. The compound of claim 1 , wherein R2 is hydrogen, halo, or C1-6-alkoxy.
7. The compound of claim 1 , wherein R3 is hydrogen, halo, or C1-6-alkoxy, optionally substituted by OH.
8. The compound of claim 1 , wherein R4 is hydrogen or C1-6-alkyl.
9. The compound of claim 1 , wherein R1, R2, R3, and R4 are hydrogen.
10. The compound of claim 1 , wherein R1, R2, R3, and R4, are each independently C1-6-alkyl or C1-6-alkoxy, optionally substituted by OH.
11. The compound of claim 1 , wherein R5 and R5′ are both hydrogen or wherein R5 and R5′ are both C1-6-alkyl.
12. The compound of claim 1 , wherein R6 is hydrogen or C1-6-alkyl.
13. The compound of claim 1 , wherein R7 and R7′ are both hydrogen.
14. The compound of claim 1 , wherein
R7 and R7′ are each independently hydrogen or halo.
15. The compound of claim 1 , wherein one of R7 and R7′ is hydrogen and the other is halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano.
16. The compound of claim 1 , wherein R8 and R8′ are each independently hydrogen, halo, or C1-6-alkoxy.
17. The compound of claim 1 , wherein
R7 and R8 or R7′ and R8′ are bound together to form a ring with the phenyl moiety, wherein
—R7-R8— or —R7′-R8′— is
—N(R10)—N═CH— or —CH═N—N(R10)—,
wherein R10 is hydrogen or C1-6-alkyl,
—N(R11)—CH═CH— or —CH═CH—N(R12)—,
wherein R11 is hydrogen or C1-6-alkyl,
—C(R12)═C(R13)—C(R14)═C(R15)—,
wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
—O—(CR16R16′)n—O—,
wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl, or
—N(R17)—CH═N— or —N═CH—N(R17)—,
wherein R17 is hydrogen or C1-6-alkyl.
18. The compound of claim 1 , wherein
R9 is hydrogen, halo, or C1-6-alkyl.
19. The compound of claim 1 , wherein
R8 and R9 or R8′ and R9′ are bound together to form a ring with the phenyl moiety, wherein
—R8-R9— or —R8′-R9— is
—C(R12)═C(R13)—C(R14)═C(R15)—,
wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
—N(R18)—C(O)—CH2—, or —CH2—C(O)—N(R18)—,
wherein R18 is hydrogen or C1-6-alkyl.
20. The compound of claim 1 , wherein R7 and R8 are bond together to form a ring with the phenyl moiety.
21. The compound of claim 1 , wherein R7′ and R8′ are bound together to form a ring with the phenyl moiety.
22. The compound of claim 24, selected from the group consisting of
5-Bromo-1′-(4-tert-butylbenzoyl)spiro[indole-3,4′-piperidin]-2(1H)-one;
5-Bromo-1′-(2-naphthoyl)spiro[indole-3,4′-piperidin]-2(1H)-one; and
1′-(4-Chlorobenzoyl)-4-methylspiro[indole-3,4′-piperidin]-2(1H)-one.
23. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
wherein
X is C═O and Y is NR6, or
X is CH2 and Y is NR6;
R1, R2, R3 and R4 are each independently
hydrogen,
halo,
C1-6-alkyl, optionally substituted by OH,
halo-C1-6-alkyl,
C1-6-alkoxy, optionally substituted by OH, or
halo-C1-6-alkoxy;
R5 and R5′ are each independently hydrogen or methyl;
R6 is hydrogen or C1-6-alkyl;
R7, R7′, R8, R8′, and R9 are each independently selected from
hydrogen,
halo,
halo-C1-6-alkyl,
C1-6-alkyl,
C1-6-alkoxy,
halo-C1-6-alkoxy,
nitro, and
cyano,
or R7 and R8, R7′ and R8′, R8 and R9, or R8′ and R9 are bound together to form a ring with the phenyl moiety, wherein
—R7-R8— or —R7′-R8′— is
—N(R10)—N═CH—, or —CH═N—N(R10)—,
wherein R10 is hydrogen or C1-6-alkyl,
—N(R11)—CH═CH—, or —CH═CH—N(R12)—,
wherein R11 is hydrogen or C1-6-alkyl,
—C(R12)═C(R13)—C(R14)═C(R15)—,
wherein R12, R13, R14, and R15 are each independently selected from hydrogen, halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, and cyano,
—O—(CR16R16′)n—O—,
wherein n is 1 or 2, and R16 and R16′ are each independently hydrogen, halo or C1-6-alkyl,
—N(R17)—CH═N—, or —N═CH—N(R17)—,
wherein R17 is hydrogen or C1-6-alkyl, or
—N(R18)—C(O)—CH2—, or —CH2—C(O)—N(R18)—,
wherein R18 is hydrogen or C1-6-alkyl,
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06127086 | 2006-12-22 | ||
EP06127086.4 | 2006-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080153862A1 true US20080153862A1 (en) | 2008-06-26 |
Family
ID=39209551
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/955,466 Abandoned US20080153863A1 (en) | 2006-12-22 | 2007-12-13 | Spiropiperidine derivatives |
US11/955,460 Abandoned US20080153862A1 (en) | 2006-12-22 | 2007-12-13 | Spiropiperidine derivatives |
US11/955,452 Expired - Fee Related US8084609B2 (en) | 2006-12-22 | 2007-12-13 | Spiropiperidine derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/955,466 Abandoned US20080153863A1 (en) | 2006-12-22 | 2007-12-13 | Spiropiperidine derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/955,452 Expired - Fee Related US8084609B2 (en) | 2006-12-22 | 2007-12-13 | Spiropiperidine derivatives |
Country Status (16)
Country | Link |
---|---|
US (3) | US20080153863A1 (en) |
EP (2) | EP2535329A3 (en) |
JP (1) | JP2010513384A (en) |
KR (1) | KR20090082502A (en) |
CN (1) | CN101563324A (en) |
AR (1) | AR064481A1 (en) |
AU (1) | AU2007338115A1 (en) |
BR (1) | BRPI0721138A2 (en) |
CA (1) | CA2673307A1 (en) |
CL (1) | CL2007003720A1 (en) |
MX (1) | MX2009006454A (en) |
NO (1) | NO20092149L (en) |
PE (1) | PE20081833A1 (en) |
RU (1) | RU2009123133A (en) |
TW (1) | TW200833697A (en) |
WO (1) | WO2008077810A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011008572A2 (en) | 2009-07-14 | 2011-01-20 | Albany Molecular Research, Inc. | 5-ht3 receptor modulators, methods of making, and use thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2670674A1 (en) * | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives as via receptor antagonists |
JP2010513384A (en) * | 2006-12-22 | 2010-04-30 | エフ.ホフマン−ラ ロシュ アーゲー | Spiro-piperidine derivatives |
AP2014008179A0 (en) | 2012-07-10 | 2014-12-31 | Bayer Pharma AG | 3-Substituted estra-1,3,5(10), 16-tetraene derivativess, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
ES2678993T3 (en) | 2013-02-21 | 2018-08-21 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5 (10), 16-tetraeno-3-carboxamides for the inhibition of dehydrogenated 17 beta-hydroxysteroid (AKR1C3) |
TW202227456A (en) | 2020-08-26 | 2022-07-16 | 美商維泰克斯製藥公司 | Inhibitors of apol1 and methods of using same |
WO2023154314A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Spiro piperidine derivatives as inhibitors of apol1 and methods of using same |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3370091A (en) * | 1964-06-15 | 1968-02-20 | Hoffmann La Roche | 2 aminobenzhydrylhalides |
US3531467A (en) * | 1966-12-23 | 1970-09-29 | Hoffmann La Roche | Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives |
US4209625A (en) * | 1977-04-21 | 1980-06-24 | American Hoechst Corporation | Spiro[indoline-3,4'-piperidine]s |
US5019587A (en) * | 1988-06-03 | 1991-05-28 | Boehringer Mannheim Gmbh | Bicyclic carboxamides, compositions containing same and use thereof |
US5670509A (en) * | 1993-09-27 | 1997-09-23 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US5885999A (en) * | 1996-01-29 | 1999-03-23 | Merck Sharp & Dohme Ltd. | Serine derivatives and their use as therapeutic agents |
US20010039286A1 (en) * | 2000-02-14 | 2001-11-08 | Kevin Dinnell | 2-aryl indole derivatives and their use as therapeutic agents |
US20020052371A1 (en) * | 1999-08-20 | 2002-05-02 | Takehiro Fukami | Novel spiro compounds |
US20040260100A1 (en) * | 2003-02-27 | 2004-12-23 | Yi-Yin Ku | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
US20080013954A1 (en) * | 2006-07-12 | 2008-01-17 | Tellabs Operations, Inc. | Multifunctional and reconfigurable optical node and optical network |
US7332501B2 (en) * | 2005-07-14 | 2008-02-19 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists |
US20080153863A1 (en) * | 2006-12-22 | 2008-06-26 | Caterina Bissantz | Spiropiperidine derivatives |
US20080171760A1 (en) * | 2007-01-12 | 2008-07-17 | Caterina Bissantz | Spiropiperidine glycinamide derivatives |
US20080281103A1 (en) * | 2006-12-29 | 2008-11-13 | Caterina Bissantz | Azaspiro derivatives |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK78692D0 (en) | 1992-06-12 | 1992-06-12 | Lundbeck & Co As H | DIMER PIPERIDINE AND PIPERAZINE DERIVATIVES |
WO1994007496A1 (en) * | 1992-10-07 | 1994-04-14 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
IT1271026B (en) | 1994-10-21 | 1997-05-26 | Isagro Ricerca Srl | DERIVATIVES OF B-AMINOPROPIONIC ACID WITH FUNGICIDE ACTIVITY |
US5576321A (en) | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
HUP9903671A3 (en) * | 1995-12-14 | 2001-11-28 | Merck & Co Inc | Antagonists of gonadotropin releasing hormone, pharmaceutical compositions and process for producing them |
US6166209A (en) | 1997-12-11 | 2000-12-26 | Hoffmann-La Roche Inc. | Piperidine derivatives |
CO5150201A1 (en) | 1998-09-07 | 2002-04-29 | Hoffmann La Roche | PIPERIDINE DERIVATIVES |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
SK286778B6 (en) | 2000-05-12 | 2009-05-07 | Solvay Pharmaceuticals B. V. | Piperazine and piperidine compounds, method for their preparation and pharmaceutical compositions comprising the same and their use |
ATE266031T1 (en) | 2000-09-29 | 2004-05-15 | Lilly Co Eli | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
BR0214455A (en) | 2001-11-27 | 2004-11-03 | Hoffmann La Roche | Benzothiazole Derivatives |
FR2833948B1 (en) | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | NOVEL BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
US20040152741A1 (en) | 2002-09-09 | 2004-08-05 | Nps Allelix Corporation | Arylglycine derivatives and their use as glycine transport inhibitors |
AU2003263155A1 (en) | 2002-09-20 | 2004-04-08 | H. Lundbeck A/S | Method for manufacture of dihydroisobenzofuran derivatives |
AU2003301436A1 (en) | 2002-10-17 | 2004-05-04 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
AU2003215549A1 (en) | 2003-02-03 | 2004-08-30 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
ATE396731T1 (en) | 2003-03-25 | 2008-06-15 | Vertex Pharma | THIAZOLES FOR USE AS INHIBITORS OF PROTEIN KINASES |
ATE482747T1 (en) * | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES |
ATE506953T1 (en) | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS |
WO2005046682A1 (en) | 2003-11-04 | 2005-05-26 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
CA2546147A1 (en) | 2003-12-23 | 2005-07-14 | Arena Pharmaceuticals, Inc. | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
WO2006013048A1 (en) | 2004-08-05 | 2006-02-09 | F.Hoffmann-La Roche Ag | Indole, indazole or indoline derivatives |
EP1802623A1 (en) | 2004-10-12 | 2007-07-04 | Novo Nordisk A/S | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds |
US20080234252A1 (en) | 2005-05-18 | 2008-09-25 | Pfizer Inc | Compounds Useful in Therapy |
EP1943250A1 (en) * | 2005-09-09 | 2008-07-16 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
CA2651396A1 (en) | 2006-05-19 | 2007-11-29 | Eisai R&D Management Co., Ltd. | Urea type cinnamide derivative |
WO2008006103A2 (en) | 2006-07-07 | 2008-01-10 | Wyeth | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
CA2670674A1 (en) | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives as via receptor antagonists |
MX2009012163A (en) | 2007-05-11 | 2009-12-01 | Hoffmann La Roche | Hetarylanilines as modulators for amyloid beta. |
US8530480B2 (en) | 2007-09-04 | 2013-09-10 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
-
2007
- 2007-12-13 JP JP2009542006A patent/JP2010513384A/en active Pending
- 2007-12-13 CN CNA2007800467360A patent/CN101563324A/en active Pending
- 2007-12-13 CA CA002673307A patent/CA2673307A1/en not_active Abandoned
- 2007-12-13 EP EP12157626A patent/EP2535329A3/en not_active Withdrawn
- 2007-12-13 WO PCT/EP2007/063879 patent/WO2008077810A2/en active Application Filing
- 2007-12-13 US US11/955,466 patent/US20080153863A1/en not_active Abandoned
- 2007-12-13 MX MX2009006454A patent/MX2009006454A/en not_active Application Discontinuation
- 2007-12-13 BR BRPI0721138-4A patent/BRPI0721138A2/en not_active IP Right Cessation
- 2007-12-13 AU AU2007338115A patent/AU2007338115A1/en not_active Abandoned
- 2007-12-13 US US11/955,460 patent/US20080153862A1/en not_active Abandoned
- 2007-12-13 US US11/955,452 patent/US8084609B2/en not_active Expired - Fee Related
- 2007-12-13 RU RU2009123133/04A patent/RU2009123133A/en not_active Application Discontinuation
- 2007-12-13 EP EP07857526A patent/EP2097376A2/en not_active Withdrawn
- 2007-12-13 KR KR1020097012736A patent/KR20090082502A/en active IP Right Grant
- 2007-12-14 PE PE2007001809A patent/PE20081833A1/en not_active Application Discontinuation
- 2007-12-19 TW TW096148806A patent/TW200833697A/en unknown
- 2007-12-20 AR ARP070105764A patent/AR064481A1/en not_active Application Discontinuation
- 2007-12-20 CL CL200703720A patent/CL2007003720A1/en unknown
-
2009
- 2009-06-03 NO NO20092149A patent/NO20092149L/en not_active Application Discontinuation
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3370091A (en) * | 1964-06-15 | 1968-02-20 | Hoffmann La Roche | 2 aminobenzhydrylhalides |
US3531467A (en) * | 1966-12-23 | 1970-09-29 | Hoffmann La Roche | Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives |
US4209625A (en) * | 1977-04-21 | 1980-06-24 | American Hoechst Corporation | Spiro[indoline-3,4'-piperidine]s |
US5019587A (en) * | 1988-06-03 | 1991-05-28 | Boehringer Mannheim Gmbh | Bicyclic carboxamides, compositions containing same and use thereof |
US5670509A (en) * | 1993-09-27 | 1997-09-23 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US5885999A (en) * | 1996-01-29 | 1999-03-23 | Merck Sharp & Dohme Ltd. | Serine derivatives and their use as therapeutic agents |
US20020052371A1 (en) * | 1999-08-20 | 2002-05-02 | Takehiro Fukami | Novel spiro compounds |
US20010039286A1 (en) * | 2000-02-14 | 2001-11-08 | Kevin Dinnell | 2-aryl indole derivatives and their use as therapeutic agents |
US20040260100A1 (en) * | 2003-02-27 | 2004-12-23 | Yi-Yin Ku | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
US7332501B2 (en) * | 2005-07-14 | 2008-02-19 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists |
US20080013954A1 (en) * | 2006-07-12 | 2008-01-17 | Tellabs Operations, Inc. | Multifunctional and reconfigurable optical node and optical network |
US20080153863A1 (en) * | 2006-12-22 | 2008-06-26 | Caterina Bissantz | Spiropiperidine derivatives |
US20080281103A1 (en) * | 2006-12-29 | 2008-11-13 | Caterina Bissantz | Azaspiro derivatives |
US20080171760A1 (en) * | 2007-01-12 | 2008-07-17 | Caterina Bissantz | Spiropiperidine glycinamide derivatives |
US7498339B2 (en) * | 2007-01-12 | 2009-03-03 | Hoffman-La Roche Inc. | Spiropiperidine glycinamide derivatives |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011008572A2 (en) | 2009-07-14 | 2011-01-20 | Albany Molecular Research, Inc. | 5-ht3 receptor modulators, methods of making, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2008077810A2 (en) | 2008-07-03 |
RU2009123133A (en) | 2011-01-27 |
MX2009006454A (en) | 2009-06-26 |
US20080153863A1 (en) | 2008-06-26 |
AU2007338115A1 (en) | 2008-07-03 |
BRPI0721138A2 (en) | 2014-04-01 |
CN101563324A (en) | 2009-10-21 |
WO2008077810A3 (en) | 2008-09-25 |
JP2010513384A (en) | 2010-04-30 |
AR064481A1 (en) | 2009-04-01 |
EP2535329A3 (en) | 2013-03-27 |
US20080153861A1 (en) | 2008-06-26 |
TW200833697A (en) | 2008-08-16 |
US8084609B2 (en) | 2011-12-27 |
EP2535329A2 (en) | 2012-12-19 |
EP2097376A2 (en) | 2009-09-09 |
NO20092149L (en) | 2009-06-18 |
CL2007003720A1 (en) | 2008-07-11 |
CA2673307A1 (en) | 2008-07-03 |
PE20081833A1 (en) | 2008-12-27 |
KR20090082502A (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8044202B2 (en) | Azaspiro derivatives | |
US8084609B2 (en) | Spiropiperidine derivatives | |
US8022213B2 (en) | Spiro-piperidine derivatives | |
US8076360B2 (en) | Indoles | |
US7678806B2 (en) | Spiro-piperidine derivatives | |
US8202993B2 (en) | Spiro-piperidine derivatives | |
US20080139618A1 (en) | Indoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BISSANTZ, CATERINA;GRUNDSCHOBER, CHRISTOPHE;MASCIADRI, RAFFAELLO;AND OTHERS;REEL/FRAME:020401/0174;SIGNING DATES FROM 20071126 TO 20071205 Owner name: HOFFMAN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMAN-LA ROCHE AG;REEL/FRAME:020401/0164 Effective date: 20071210 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |